MRSA (Methicillin-Resistant Staphylococcus Aureus) Infection
The History of MRSAStaphylococcus aureus, or S. aureus, is commonly known as "staph." This bacterium was discovered in the 1880s. During this era, S. aureus infections most often caused painful skin and soft tissue conditions, such as boils and impetigo.
In the 1940s, medical treatment for S. aureus infections became routine and successful with the discovery and introduction of antibiotic medication, such as penicillin.
From that point on, however, the use of antibiotics (including misuse and overuse) has aided natural bacterial evolution by helping the microbes become resistant to drugs designed to help fight these infections.
In the late 1940s and throughout the 1950s, S. aureus developed resistance to penicillin. Methicillin, a form of penicillin, was introduced to counter the increasing problem of penicillin-resistant S. aureus. Methicillin was one of the most common types of antibiotics used to treat S. aureus infections. However, in 1961, British scientists identified the first strains of S. aureus bacteria that resisted methicillin. This was the so-called birth of MRSA.
The first reported human case of MRSA in the United States occurred in 1968. Subsequently, new strains of bacteria have developed that can now resist previously effective drugs, such as methicillin and most related antibiotics.
S. aureus is evolving even more and has begun to show resistance to additional antibiotics. In 2002, physicians in the United States documented the first S. aureus strains resistant to the antibiotic vancomycin (Vancocin®), which had been one of a handful of antibiotics of last resort for use against S. aureus. Though it is feared that this could quickly become a major issue in antibiotic resistance, thus far, vancomycin-resistant strains are still rare at this time.